Hydroxychloroquine Decreases Disease Activity in Pregnant Women with Lupus
New research affirms the safety and efficacy of women with lupus taking hydroxychloroquine (HCQ) or Plaquenil® as prescribed during pregnancy. Women who took their medication throughout pregnancy saw a decreased likelihood of high lupus activity during their pregnancy and without any increased risk of negative outcomes, such as fetal loss, preterm delivery, or pre-eclampsia.
Scientists conducted a large-scale review of data of 962 pregnancies of women around the globe and of multiple races and ethnicities. The women enrolled in their respective study groups (seven total) during their first trimester and were managed by a rheumatologist specializing in pregnancy. Women taking HCQ as directed during their pregnancy saw decreased odds (95%) of high disease activity.
Women who took HCQ as directed also saw low lupus activity early in their first trimester. And HCQ treatment was associated with a lower odds of preterm delivery.
Women with lupus can have healthy pregnancies. Taking HCQ can contribute to healthy outcomes. Learn more about lupus and pregnancy.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.